Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q4 2023 · 10-K
Revenue$149.75M$149.75M+15.5% vs Q4 2022 Net Income$31.94M$31.94MN/M vs Q4 2022 EPS Diluted$0.82$0.82N/M vs Q4 2022 Gross Profit$94,630,000+90.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flowderived$73,338,000+10.6% Free Cash Flowderived$73,174,000+11.9% Margins · derivedGross margin63.2%+24.8 pt vs Q4 2022
Operating margin41.2%+32.1 pt vs Q4 2022
Net margin21.3%+26.9 pt vs Q4 2022
ended Dec 31, 2023 · filed Feb 22, 2024 · 53 d after period end